ReviewMedicine2025
Glioblastoma insights: Focus on crosstalk with the suppressive tumor microenvironment and advanced therapeutic strategies.
Review in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Glioblastoma (GBM) is an extremely aggressive brain tumor for which there is currently no curative therapy available. The tumor microenvironment comprises an intricate interplay of various cells and molecules. Recent research has increasingly emphasized the inhibitory characteristics of the microenvironment, which significantly influence tumor growth, proliferation, and response to therapy through mechanisms including immunosuppression, hypoxia, and nutritional deficits. Comprehension of the crosstalk between GBM and the suppressive tumor microenvironment has the potential to advance future investigations aimed at surmounting this inhibitory microenvironment. Additionally, it could offer guidance for the formulation of novel therapeutic approaches. Significantly, we reviewed advanced therapeutic strategies to overcome GBM, such as immune checkpoint inhibitors, chimeric antigen receptor therapies, nanoparticles, small molecule inhibitors, and stem cell-based therapies. These strategies are continuously evolving and being improved, with the potential to significantly augment the therapeutic effectiveness against GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.